Cytogenetic and Molecular Features of Mixed Phenotype Acute Leukemia and the Impacts of Targeted Therapy
Insights in Blood Disorders · 2025
DOI: 10.33425/2771-9073.1018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Insights in Blood Disorders, 2025. Verfasst von Jordan Selep DO und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Currently, there is no treatment consensus on the optimal treatment regimen for mixed-phenotype acute leukemia (MPAL).
Aims
To analyze the cytogenetic and molecular characteristics of U.S. veterans diagnosed with MPAL as well as examine the effects of targeted therapy on their overall survival.
Methods
Retrospective study between the years 2000-2023 Setting: U.S. Department of Veterans Affairs Participants: United states veterans in the Veterans Affairs Informatics and Computing Infrastructure (VINCI) database diagnosed with MPAL between 2000-2023. The text utilization integration feature was used to query all notes which included the phrases “mixed phenotype acute leukemia”, “MPAL”, and “biphenotypic leukemia” and identified 320 patients. All patient charts were reviewed manually. 94 patients were included in the final analysis. Exposure: Treatment for MPAL. Main outcomes and measures: The primary outcome was 5-year overall survival (OS), KaplanMeier and Cox regression analyses were used to compare this between different patient groups.
Results
Of the 74 patients treated with curative intent, 33 patients had potentially targetable mutations and 21 patients received targeted therapy. The 5-year OS for the entire cohort was 26%. Mutations noted in more than one patient included RUNX1 (n=10), NOTCH1 (n=4), DNMT3A (n=4). For the purposes of the study, TP53, TET2, and inv(16) were removed from the model due to small number of positive patients. Patients with Ph, RUNX1, and FLT3 mutations had improved OS with HR of 0.21 (p=0.09) with patients older than 80 years in age, with the worst outcomes, HR 11.9 (p=0.008). Patients who were sent to transplant in their first clinical remission (CR1) had better outcomes with HR 0.14 (p=
Zitieren
APA
DO, J. S., McKinnell, Z., Degann, S., Karel, D., Liu, S., Diao, G., Antonio, M., Neppalli, A., Nassereddine, S., & Jain, M. R. (2025). Cytogenetic and Molecular Features of Mixed Phenotype Acute Leukemia and the Impacts of Targeted Therapy. Insights in Blood Disorders. https://doi.org/10.33425/2771-9073.1018
Vancouver
DO JS, McKinnell Z, Degann S, Karel D, Liu S, Diao G, et al. Cytogenetic and Molecular Features of Mixed Phenotype Acute Leukemia and the Impacts of Targeted Therapy. Insights in Blood Disorders. 2025. doi:10.33425/2771-9073.1018
BibTeX
@article{DO2025,
author = {DO, Jordan Selep and McKinnell, Zoe and Degann, Seta and Karel, Daniel and Liu, Shanshan and Diao, Guoqing and Antonio, Martha and Neppalli, Amarendra and Nassereddine, Samah and Jain, Maneesh Rajiv},
title = {Cytogenetic and Molecular Features of Mixed Phenotype Acute Leukemia and the Impacts of Targeted Therapy},
journal = {Insights in Blood Disorders},
year = {2025},
doi = {10.33425/2771-9073.1018}
}
EUVIMED